To date, very little data exists on gliomas in the Réunion population, in terms of epidemiology, socio-cultural aspects, clinical or biological factors, and care pathways. However, the Réunion population is multicultural and highly cosmopolitan, experiencing rapid aging, and its socio-economic indicators are among the most pessimistic of all French departments. Furthermore, the healthcare services available on the island are less comprehensive than those in metropolitan France (Insee 2018). Finally, the management of patients with gliomas, particularly high-grade gliomas, remains very complex, with significant medical and social challenges (supportive care, end-of-life care, etc.). Healthcare professionals agree that these specialized facilities are insufficient to meet the care needs in Réunion (post-acute care, palliative care units, supportive care, etc.).
GlioRun is a retrospective and prospective mixed-methods cohort study, combining epidemiological and socio-anthropological approaches, which aims to produce data to improve care and the experiences of patients and their relatives on Reunion Island, and reduce the number of medical evacuations to mainland France.
With a histological diagnosis of incident diffuse glioma since January 1, 2018
Residing in Réunion at the time of diagnosis,
Having been informed about the study procedures
Having agreed to participate in the study
None
person with glioma at La Réunion Island
Cohort
Cross-sectional
Not listed
Distribution of sociodemographic characteristics at diagnosis
Distribution of age at diagnosis (years), sex (male/female), ethnicity, and socioeconomic indicators among patients diagnosed with diffuse glioma in Réunion Island
Clinical presentation of diffuse gliomas at diagnosis
Clinical characteristics at diagnosis including presenting symptoms, performance status (e.g., Karnofsky Performance Status score), tumor location, and initial treatment modalities
Molecular characteristics of diffuse gliomas
Tumor molecular markers including IDH mutation status, 1p/19q codeletion status, and MGMT promoter methylation status assessed at diagnosis
Histopathological classification of diffuse gliomas
Histopathological classification of tumors according to the WHO classification of central nervous system tumors at diagnosis
Click on the lead sponsor to view all of their trials.
